/PRNewswire/ -- The "Viral Vectors and Plasmid DNA Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. Substantial Growth...
/PRNewswire/ -- The "Cancer Gene Therapy Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering. The cancer gene...
/PRNewswire/ -- The "Global Drug Delivery Devices Market (2021-2026) by device type, route of administration, application, end-user, vehicle outlook,...
/PRNewswire/ -- The "Global Drug Delivery Devices Market (2021-2027) by device type, route of administration, application, end-user, vehicle outlook, and...
/PRNewswire/ -- The "Global Drug Delivery Devices Market (2021-2027) by device type, route of administration, application, end-user, vehicle outlook, and...
Global Drug Delivery Devices Markets, 2020-2025 - Opportunities in the Growth in Nanotechnology and Technological Advancements prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com's offering.
Viral Vectors & Plasmid DNA Global Market Report 2020-30: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global viral vectors & plasmid dna market.
Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Cell and Gene Therapy Catapult, VGXI, and MassBiologics.
The global viral vectors & plasmid DNA market is expected to grow from $0.46 billion in 2019 to $0.60 billion in 2020 at a compound annual growth rate (CAGR) of 31.3%. The growth is mainly due to the outbreak of COVID 19 and requires targeted delivery of the drug to treat affected patients. The number of cases has been increasing resulting in a surge in demand for viral vectors & plasmid DNA. The market is expected to reach $1.05 billion in 2023 at a CAGR of 20.4%.